Navigation Links
Encision Reports 14% Revenue Increase in Second Quarter Results
Date:10/24/2011

BOULDER, Colo., Oct. 24, 2011 /PRNewswire/ -- Encision Inc. (ECIA:PK), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its second fiscal quarter ended September 30, 2011.

The Company recorded a net loss of $469,000 or $(0.07) per share for the second quarter of fiscal year 2012 on net product revenue of $2.830 million and net service revenue of $437 thousand. Total revenue of $3.267 million represented a 14% increase from total revenue of $2.866 million for the second quarter of fiscal year 2011. The Company recorded a $145,000 net loss, or $(0.02) per share for the second quarter of fiscal year 2011. The net loss of $469,000 for the second quarter of fiscal year 2012 included approximately $500,000 of one-time charges. The one-time charges were $430,000 for a voluntary recall of certain electrode product, as announced in the Company's press release of October 17, 2011, and separation expense for the Company's former President and CEO.

Gross profit margin, on total revenue, for the second quarter of fiscal year 2012 was 48% as compared to 64% for the second quarter of fiscal year 2011. The gross profit margin decrease from the second quarter of fiscal year 2011 was due to the charge for a voluntary recall, as explained above, and an increase, as a percentage of revenue, of lower gross margin revenue. Excluding the voluntary recall cost, gross profit margin for the second quarter of fiscal year 2012 was 61%.

The Company recorded a net loss of $490,000 or $(0.08) per share for the first six months ended September 30, 2011 on net product revenue of $5.664 million and net service revenue of $787 thousand. Total revenue of $6.451 million represented a 12% increase from total revenue of $5.778 million for the first six months ended September 30, 2010. The Company recorded a $264,000 net loss, or $(0.04) per share for the first six months ended September 30, 2010.

Gross profit margin, on total revenue, for the first six months ended September 30, 2011 was 52% as compared to 64% for the first six months ended September 30, 2010. The gross profit margin decrease from the first six months ended September 30, 2010 was due to the items that were explained above.

"Although the Company has suffered a setback due to the recall, we will continue to maintain our devotion to producing quality instruments for our customers," said Fred Perner, Encision's new President and CEO.  "Our mission includes the improvement of patient outcomes and the enhancement of patient safety. A culture of quality is paramount to achieving that mission. In my short time here, I have witnessed the commitment that our employees have to that culture and have personally seen what our technology means to surgeons and patients."

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2010 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:   Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.comEncision Inc.Condensed Balance Sheets(Amounts in thousands)(Unaudited)September 30,2011March 31, 2011ASSETSCash and cash equivalents$
5$
20Accounts receivable, net1,1011,160Inventories, net2,6892,604Prepaid expenses12274Total current assets3,9273,958Equipment, net1,3811,169Patents, net269260Other assets124Total assets$ 5,578$ 5,411LIABILITIES AND SHAREHOLDERS' EQUITYAccounts payable$
728$
74Accrued compensation233261Other accrued liabilities617287Line of credit691435Total current liabilities2,2691,657Common stock and additional paid-in capital19,82819,783Accumulated (deficit)(16,519)(16,029)Total shareholders' equity3,3093,754Total liabilities and shareholders' equity$ 5,578$  5,411Encision Inc.Condensed Statements of Operations(Amounts in thousands, except per share information)(Unaudited)Three Months EndedSix Months EndedSeptember 30,2011September 30,2010September 30,2011September 30,2010Net revenue:Product$ 2,830$ 2,866$ 5,664$ 5,729Service437––78749Total revenue3,2672,8666,4515,778Cost of revenue:Product1,5251,0322,7862,055Service176––32045Total cost of revenue1,7011,0323,1062,100Gross profit1,5661,8343,3453,678Operating expenses:Sales and marketing1,2131,0752,2502,261General and administrative463397882793Research and development342495673867Total operating expenses2,0181,9673,8053,921Operating loss(452)(133)(460)(243)Interest and other income (expense), net(17)(12)(30)(21)Loss before provision for income taxes(469)(145)(490)(264)Provision for income taxes––––––––Net loss$  (469)$   (145)$
(490)$   (264)Net loss per share—basic and diluted$ (0.07)$ (0.02)$   (0.08)$ (0.04)Basic  and diluted weighted average number of shares6,4556,4556,4556,455
'/>"/>

SOURCE Encision Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Encision Reports Profitable Third Fiscal Quarter Results
2. Encision and HealthTrust Purchasing Group Sign Purchasing Agreement
3. Encisions Technology Recognized as A Means to Eliminate Surgery Burns
4. Encisions Active Electrode Monitoring Technology Recommended at Minimally Invasive Gynecology Congress
5. Encision Reports Profitable Fourth Quarter and Fiscal Year 2011 Results
6. Encision Reports 9.3% Revenue Increase in First Quarter Results
7. Encision Announces Leadership Change
8. Encision Announces Voluntary Recall of Certain Electrode Product
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
Breaking Medicine News(10 mins):